Fuji Pharma’s stock has been grinding lower for months, yet the latest earnings land with a very different message. The share price closed at ¥1,773 on 7 August after a weak run over 7, 30 and 90 days, while the business just reported one of its stronger profit quarters.
The headline is clear. Basic earnings per share rose to ¥42.38 in Q3 on net income of ¥1,107m, even as trailing net margin stands at 5% and still reflects a sizeable one off loss of ¥3.7b in the last twelve months. Sentiment points to fatigue, while the figures point to a profit story that investors are still pricing cautiously.
Impressed by Fuji Pharma’s latest profit delivery but cautious about the recent share price slide and prior one off loss? Take a look at our carefully filtered list of list of solid balance sheet and fundamentals stocks (40 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): ¥15,666m vs. ¥12,859m (up about 21.8%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): ¥1,107m vs. ¥543m (up about 103.9%)
- Basic EPS (Q3 2026 vs Q3 2025): ¥42.38 vs. ¥22.23 (up about 90.7%)
- Trailing Net Margin (Last 12 Months vs Prior Year): 5.0% vs. 6.1% (margin has narrowed)
Prefer clean visuals instead of another wall of earnings tables and raw figures? View Fuji Pharma’s full financial picture, with a focus on its valuation, in an easy to scan visual format in our company report for Fuji Pharma.
Fuji Pharma earnings tilt narrative toward the bulls
For investors who see Fuji Pharma as a defensive healthcare stock, this quarter gives that view more weight. Revenue of ¥15,666m and basic EPS of ¥42.38 both stand well ahead of the prior year period, while net income excluding extra items has roughly doubled. That points to a business model currently converting sales into profit more efficiently, even with a modest 5% trailing net margin. The profit rebound also sits at odds with the recent 90 day share price slide, which suggests sentiment has weakened faster than the core financial picture.
Short term risks still visible in Fuji Pharma story
There is enough in these numbers to support a cautious stance as well. The trailing net margin of 5% is lower than the prior 6.1% and still carries the imprint of a sizeable ¥3.7b one off loss in the last twelve months. That combination helps explain why Fuji Pharma’s share price is down about 21% over 90 days despite stronger Q3 figures. The data implies a company that is profitable right now, but with recent earnings volatility that some investors may see as a live risk rather than a closed chapter.
Compare this profit rebound in Fuji Pharma with what institutional analysts are signalling. See the consensus price target analysis for Fuji Pharma to check whether the street expects the recent earnings strength to translate into a different path for the stock.Take Control of Your Next Move
If Fuji Pharma’s mix of recent share price weakness and stronger Q3 profits has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and spot an entry point that fits your plan. Once you are invested, keep your Fuji Pharma position in focus with the Portfolio Command Center that filters out noise and highlights only the key developments that matter to your holdings. For a broader view on what other investors are thinking, use the Community to tap into different perspectives and questions around the stock. By surfacing potential catalysts and risks early, you give yourself a better chance to react quickly and stay a step ahead of the market.
Seeking Fresh Alternatives Beyond Fuji Pharma
Some stocks are building quiet momentum while others are dropping out of focus. Consider these fresh ideas before the crowd catches on and the clean entry points vanish.
- Spot companies where strong balance sheets back real staying power by scanning our curated list of solid balance sheet and fundamentals stocks (40 results) before that strength is fully reflected in prices.
- Explore higher income potential with carefully screened 43 dividend fortresses that may offer sizeable yields while they are still flying under the radar.
- Focus on future critical materials through a targeted set of 28 best rare earth metal stocks before momentum screens highlight the same opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com